The IRIS-Resolute Integrity (IRIS-Integrity)
Launched by SEUNG-JUNG PARK · Jul 12, 2011
Trial Information
Current as of June 21, 2025
Completed
Keywords
ClinConnect Summary
Consecutive Percutaneous Coronary Intervention patients receiving Resolute Integrity stent will be compared with other concurrent Drug Eluting Stents.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with significant coronary artery disease and receiving Resolute Integrity stent.
- • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
- Exclusion Criteria:
- • Patients with a mixture of other DESs
- • Terminal illness with life expectancy \<1 year
- • Patients presented with cardiogenic shock
About Seung Jung Park
Seung-Jung Park is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and innovation. With a focus on cardiology and interventional procedures, he leads initiatives that aim to improve patient outcomes through rigorous clinical trials. His expertise in trial design and execution ensures adherence to the highest ethical standards and regulatory requirements. By fostering collaboration among multidisciplinary teams, Seung-Jung Park drives the development of cutting-edge therapies, contributing significantly to the scientific community and enhancing the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Ulsan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Kwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Jeonju, , Korea, Republic Of
Anyang, , Korea, Republic Of
Ilsan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Incheon, , Korea, Republic Of
Pusan, , Korea, Republic Of
Suncheon, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Ilsan, Gyeong Gi, Korea, Republic Of
Bucheon, , Korea, Republic Of
Bucheon, , Korea, Republic Of
Uijeongbu, , Korea, Republic Of
Gangneung, , Korea, Republic Of
Patients applied
Trial Officials
Seung-Jung Park, MD, PhD
Principal Investigator
Asan Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials